A validated LC-MS/MS method of total and unbound lenvatinib quantification in human serum for protein binding studies by equilibrium dialysis.
Mano Y, Kusano K.
J Pharm Biomed Anal · validation study; journal article · DOI 10.1016/j.jpba.2015.05.008 PUBLIKATIONSREGISTRET
Gå till forskningen.
Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.
Publikationer som ChEBI hänvisar till för lenvatinib mesylate. Visa hela publikationsregistret
En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.
Publikationer i urvalet
12 träffarA phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: A clinical outcomes and biomarker assessment.
Cabanillas ME, Schlumberger M, Jarzab B, Martins RG, Pacini F, Robinson B, McCaffrey JC, Shah MH, Bodenner DL, Topliss D, Andresen C, O'Brien JP, Ren M, Funahashi Y, Allison R, Elisei R, Newbold K, Licitra LF, Sherman SI, Ball DW.
Cancer · clinical trial, phase ii; research support, non-u.s. gov't; research-article; journal article · DOI 10.1002/cncr.29395Lenvatinib: first global approval.
Scott LJ.
Drugs · review; journal article · DOI 10.1007/s40265-015-0383-0Pharmaceutical approval update.
Gohil K.
P T · other; journal articleA review of 2014 cancer drug approvals, with a look at 2015 and beyond.
Butler T, Maravent S, Boisselle J, Valdes J, Fellner C.
P T · research-article; journal articleE7080 (lenvatinib), a multi-targeted tyrosine kinase inhibitor, demonstrates antitumor activities against colorectal cancer xenografts.
Wiegering A, Korb D, Thalheimer A, Kämmerer U, Allmanritter J, Matthes N, Linnebacher M, Schlegel N, Klein I, Ergün S, Germer CT, Otto C.
Neoplasia · research support, non-u.s. gov't; research-article; journal article · DOI 10.1016/j.neo.2014.09.008Antitumor activity of lenvatinib (e7080): an angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models.
Tohyama O, Matsui J, Kodama K, Hata-Sugi N, Kimura T, Okamoto K, Minoshima Y, Iwata M, Funahashi Y.
J Thyroid Res · research-article; journal article · DOI 10.1155/2014/638747Effect of rifampicin on the pharmacokinetics of lenvatinib in healthy adults.
Shumaker RC, Aluri J, Fan J, Martinez G, Thompson GA, Ren M.
Clin Drug Investig · research support, non-u.s. gov't; research-article; clinical trial, phase i; journal article · DOI 10.1007/s40261-014-0217-yEffect of lenvatinib (E7080) on the QTc interval: results from a thorough QT study in healthy volunteers.
Shumaker RC, Zhou M, Ren M, Fan J, Martinez G, Aluri J, Darpo B.
Cancer Chemother Pharmacol · randomized controlled trial; journal article · DOI 10.1007/s00280-014-2444-6Evaluation of the effects of formulation and food on the pharmacokinetics of lenvatinib (E7080) in healthy volunteers.
Shumaker R, Aluri J, Fan J, Martinez G, Ren M, Chen K.
Int J Clin Pharmacol Ther · research support, non-u.s. gov't; clinical trial, phase i; randomized controlled trial; journal article · DOI 10.5414/cp201937Anticancer effect of COX-2 inhibitor DuP-697 alone and in combination with tyrosine kinase inhibitor (E7080) on colon cancer cell lines.
Altun A, Turgut NH, Kaya TT.
Asian Pac J Cancer Prev · research support, non-u.s. gov't; journal article · DOI 10.7314/apjcp.2014.15.7.3113A phase 1b clinical trial of the multi-targeted tyrosine kinase inhibitor lenvatinib (E7080) in combination with everolimus for treatment of metastatic renal cell carcinoma (RCC).
Molina AM, Hutson TE, Larkin J, Gold AM, Wood K, Carter D, Motzer R, Michaelson MD.
Cancer Chemother Pharmacol · research support, non-u.s. gov't; research-article; clinical trial, phase i; journal article · DOI 10.1007/s00280-013-2339-y